| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Technology Assessment, Biomedical | 28 | 2024 | 306 | 5.970 |
Why?
|
| Cost-Benefit Analysis | 78 | 2024 | 5508 | 4.830 |
Why?
|
| Decision Support Techniques | 32 | 2020 | 2001 | 3.670 |
Why?
|
| Quality-Adjusted Life Years | 40 | 2024 | 1724 | 3.430 |
Why?
|
| Austria | 33 | 2024 | 206 | 2.850 |
Why?
|
| Early Detection of Cancer | 18 | 2023 | 3202 | 2.670 |
Why?
|
| Markov Chains | 32 | 2024 | 968 | 2.550 |
Why?
|
| Germany | 46 | 2024 | 873 | 2.220 |
Why?
|
| Mining | 9 | 2020 | 91 | 1.990 |
Why?
|
| Comparative Effectiveness Research | 10 | 2019 | 718 | 1.960 |
Why?
|
| Mass Screening | 23 | 2023 | 5423 | 1.790 |
Why?
|
| Mistletoe | 2 | 2023 | 2 | 1.730 |
Why?
|
| Viscum album | 2 | 2023 | 4 | 1.730 |
Why?
|
| Models, Economic | 11 | 2021 | 719 | 1.680 |
Why?
|
| Equipment and Supplies | 4 | 2022 | 275 | 1.570 |
Why?
|
| Models, Theoretical | 14 | 2021 | 3562 | 1.490 |
Why?
|
| Decision Making | 21 | 2017 | 3925 | 1.460 |
Why?
|
| Iodine | 4 | 2020 | 286 | 1.460 |
Why?
|
| Mercury | 8 | 2020 | 290 | 1.420 |
Why?
|
| Hepatitis C, Chronic | 11 | 2019 | 1031 | 1.360 |
Why?
|
| Quality of Life | 31 | 2024 | 13308 | 1.290 |
Why?
|
| Gold | 9 | 2020 | 484 | 1.220 |
Why?
|
| Policy Making | 3 | 2022 | 538 | 1.150 |
Why?
|
| Breast Neoplasms | 15 | 2023 | 21025 | 1.120 |
Why?
|
| Ribavirin | 8 | 2019 | 396 | 1.090 |
Why?
|
| Uterine Cervical Neoplasms | 8 | 2022 | 2003 | 1.060 |
Why?
|
| Antiviral Agents | 11 | 2019 | 3061 | 1.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2015 | 685 | 1.060 |
Why?
|
| Health Care Costs | 23 | 2021 | 3258 | 1.060 |
Why?
|
| Models, Statistical | 13 | 2022 | 5075 | 1.030 |
Why?
|
| Status Epilepticus | 3 | 2020 | 456 | 1.020 |
Why?
|
| Porpoises | 3 | 2020 | 4 | 0.980 |
Why?
|
| Ovarian Neoplasms | 4 | 2023 | 4878 | 0.970 |
Why?
|
| Interferon-alpha | 8 | 2019 | 918 | 0.940 |
Why?
|
| Risk Management | 2 | 2024 | 558 | 0.940 |
Why?
|
| Humans | 313 | 2024 | 760621 | 0.930 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2023 | 1394 | 0.890 |
Why?
|
| Deficiency Diseases | 2 | 2020 | 74 | 0.880 |
Why?
|
| Fractional Flow Reserve, Myocardial | 7 | 2019 | 329 | 0.840 |
Why?
|
| Environmental Monitoring | 7 | 2020 | 1441 | 0.820 |
Why?
|
| Europe | 18 | 2024 | 3441 | 0.820 |
Why?
|
| Papillomavirus Infections | 6 | 2022 | 1607 | 0.810 |
Why?
|
| Leg Ulcer | 1 | 2021 | 70 | 0.750 |
Why?
|
| Evidence-Based Practice | 4 | 2017 | 496 | 0.750 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2024 | 10344 | 0.740 |
Why?
|
| Phocoena | 1 | 2020 | 2 | 0.730 |
Why?
|
| Coronary Angiography | 31 | 2019 | 4563 | 0.730 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2022 | 384 | 0.730 |
Why?
|
| Guidelines as Topic | 9 | 2024 | 1392 | 0.720 |
Why?
|
| Mammography | 5 | 2017 | 2427 | 0.710 |
Why?
|
| Mercury Compounds | 2 | 2009 | 7 | 0.700 |
Why?
|
| Evidence-Based Medicine | 10 | 2022 | 3696 | 0.700 |
Why?
|
| Hepatitis C | 7 | 2009 | 1579 | 0.700 |
Why?
|
| Mercury Poisoning | 2 | 2009 | 32 | 0.690 |
Why?
|
| Survival Analysis | 16 | 2020 | 10182 | 0.690 |
Why?
|
| Troponin I | 1 | 2024 | 638 | 0.690 |
Why?
|
| Life Expectancy | 10 | 2020 | 1248 | 0.680 |
Why?
|
| Malus | 1 | 2020 | 50 | 0.670 |
Why?
|
| Uncertainty | 7 | 2022 | 754 | 0.670 |
Why?
|
| Hepacivirus | 4 | 2013 | 1334 | 0.670 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2023 | 626 | 0.650 |
Why?
|
| Computer Simulation | 8 | 2019 | 6218 | 0.650 |
Why?
|
| Resistance Training | 4 | 2020 | 185 | 0.650 |
Why?
|
| Thyroid Diseases | 2 | 2020 | 386 | 0.650 |
Why?
|
| Middle Aged | 130 | 2024 | 220352 | 0.630 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 6853 | 0.620 |
Why?
|
| Coronary Artery Disease | 18 | 2019 | 6659 | 0.620 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2023 | 1223 | 0.620 |
Why?
|
| Drug Substitution | 3 | 2016 | 296 | 0.610 |
Why?
|
| Female | 161 | 2024 | 391270 | 0.610 |
Why?
|
| Heart Failure | 14 | 2024 | 11847 | 0.610 |
Why?
|
| Clinical Coding | 1 | 2019 | 181 | 0.610 |
Why?
|
| gamma-Glutamylcyclotransferase | 1 | 2017 | 8 | 0.600 |
Why?
|
| Economics, Pharmaceutical | 4 | 2020 | 88 | 0.600 |
Why?
|
| Budgets | 1 | 2019 | 230 | 0.590 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 1717 | 0.590 |
Why?
|
| Dyspnea | 3 | 2021 | 1352 | 0.580 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 1189 | 0.580 |
Why?
|
| Stroke | 7 | 2023 | 9962 | 0.570 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2022 | 396 | 0.570 |
Why?
|
| Cost of Illness | 9 | 2018 | 1940 | 0.560 |
Why?
|
| National Health Programs | 6 | 2020 | 441 | 0.560 |
Why?
|
| Aged | 100 | 2024 | 169152 | 0.560 |
Why?
|
| Research Design | 13 | 2024 | 6180 | 0.550 |
Why?
|
| Parkinson Disease | 13 | 2016 | 2859 | 0.520 |
Why?
|
| Medical Errors | 1 | 2024 | 1255 | 0.520 |
Why?
|
| Selection Bias | 3 | 2019 | 358 | 0.510 |
Why?
|
| Preventive Health Services | 1 | 2020 | 570 | 0.510 |
Why?
|
| Coronary Stenosis | 11 | 2006 | 820 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3334 | 0.510 |
Why?
|
| Immunization Programs | 2 | 2009 | 268 | 0.510 |
Why?
|
| Blood Vessel Prosthesis Implantation | 7 | 2023 | 1446 | 0.510 |
Why?
|
| Stents | 19 | 2011 | 3314 | 0.490 |
Why?
|
| Noise, Transportation | 2 | 2020 | 51 | 0.490 |
Why?
|
| Neoplasms | 9 | 2020 | 22072 | 0.490 |
Why?
|
| Angioplasty, Balloon, Coronary | 16 | 2011 | 1880 | 0.490 |
Why?
|
| Adult | 86 | 2024 | 219994 | 0.480 |
Why?
|
| Vaginal Smears | 4 | 2020 | 495 | 0.480 |
Why?
|
| Advisory Committees | 4 | 2013 | 788 | 0.480 |
Why?
|
| Drug Industry | 3 | 2018 | 789 | 0.470 |
Why?
|
| Coronary Disease | 18 | 2011 | 5990 | 0.470 |
Why?
|
| Delivery of Health Care | 9 | 2022 | 5325 | 0.470 |
Why?
|
| Mortality | 4 | 2020 | 2916 | 0.470 |
Why?
|
| Cross-Cultural Comparison | 3 | 2011 | 633 | 0.460 |
Why?
|
| Risk Assessment | 24 | 2024 | 24123 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2018 | 613 | 0.460 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 894 | 0.460 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 1824 | 0.460 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 786 | 0.460 |
Why?
|
| Ultrasonography, Interventional | 16 | 2009 | 1502 | 0.450 |
Why?
|
| Expert Testimony | 1 | 2016 | 361 | 0.450 |
Why?
|
| Male | 140 | 2024 | 359744 | 0.450 |
Why?
|
| Peptide Fragments | 3 | 2021 | 5125 | 0.440 |
Why?
|
| Coronary Restenosis | 10 | 2009 | 426 | 0.430 |
Why?
|
| Medical Order Entry Systems | 2 | 2009 | 522 | 0.430 |
Why?
|
| Work Capacity Evaluation | 1 | 2013 | 45 | 0.430 |
Why?
|
| Drugs, Generic | 2 | 2015 | 448 | 0.430 |
Why?
|
| Health Expenditures | 2 | 2016 | 2362 | 0.420 |
Why?
|
| Health Services Research | 2 | 2020 | 1810 | 0.420 |
Why?
|
| Data Collection | 7 | 2017 | 3315 | 0.410 |
Why?
|
| Sensitivity and Specificity | 30 | 2021 | 14660 | 0.410 |
Why?
|
| Internationality | 3 | 2015 | 1004 | 0.410 |
Why?
|
| Diabetic Foot | 3 | 2024 | 381 | 0.410 |
Why?
|
| Data Interpretation, Statistical | 7 | 2013 | 2696 | 0.410 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 424 | 0.410 |
Why?
|
| Papillomavirus Vaccines | 2 | 2009 | 495 | 0.400 |
Why?
|
| Occupational Exposure | 5 | 2017 | 1809 | 0.400 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2012 | 146 | 0.390 |
Why?
|
| Loneliness | 2 | 2024 | 197 | 0.390 |
Why?
|
| Occult Blood | 5 | 2023 | 197 | 0.390 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 928 | 0.390 |
Why?
|
| Veterans Health | 1 | 2013 | 216 | 0.390 |
Why?
|
| Treatment Outcome | 43 | 2024 | 65017 | 0.370 |
Why?
|
| Financing, Personal | 1 | 2013 | 309 | 0.370 |
Why?
|
| Phytotherapy | 2 | 2023 | 295 | 0.370 |
Why?
|
| Antiparkinson Agents | 6 | 2016 | 183 | 0.370 |
Why?
|
| Population Surveillance | 2 | 2018 | 2608 | 0.360 |
Why?
|
| Perinatal Mortality | 1 | 2011 | 101 | 0.360 |
Why?
|
| Hazardous Substances | 1 | 2011 | 152 | 0.360 |
Why?
|
| Decision Trees | 2 | 2021 | 506 | 0.360 |
Why?
|
| Abdominal Fat | 1 | 2012 | 223 | 0.350 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2011 | 190 | 0.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2022 | 3224 | 0.340 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5251 | 0.340 |
Why?
|
| Disease Management | 5 | 2024 | 2514 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 5643 | 0.340 |
Why?
|
| Cooperative Behavior | 5 | 2015 | 1500 | 0.340 |
Why?
|
| Program Evaluation | 5 | 2020 | 2493 | 0.330 |
Why?
|
| Colonoscopy | 5 | 2023 | 1387 | 0.330 |
Why?
|
| Ambulatory Care Facilities | 3 | 2013 | 926 | 0.330 |
Why?
|
| Endovascular Procedures | 1 | 2023 | 2165 | 0.330 |
Why?
|
| Coronary Circulation | 10 | 2005 | 1577 | 0.320 |
Why?
|
| Economics, Medical | 5 | 2023 | 112 | 0.320 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15757 | 0.320 |
Why?
|
| Registries | 12 | 2020 | 8469 | 0.320 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 374 | 0.320 |
Why?
|
| Zimbabwe | 4 | 2020 | 135 | 0.310 |
Why?
|
| Aircraft | 1 | 2009 | 126 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 11712 | 0.310 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 218 | 0.310 |
Why?
|
| Simvastatin | 1 | 2011 | 352 | 0.310 |
Why?
|
| Environmental Pollutants | 4 | 2023 | 1266 | 0.300 |
Why?
|
| Prostatic Neoplasms | 6 | 2017 | 11345 | 0.300 |
Why?
|
| Quarantine | 2 | 2020 | 176 | 0.300 |
Why?
|
| Seals, Earless | 3 | 2020 | 11 | 0.300 |
Why?
|
| Aged, 80 and over | 32 | 2024 | 58995 | 0.300 |
Why?
|
| Health Care Rationing | 3 | 2010 | 435 | 0.290 |
Why?
|
| Electronic Prescribing | 1 | 2008 | 114 | 0.290 |
Why?
|
| Marketing of Health Services | 1 | 2008 | 150 | 0.280 |
Why?
|
| Health Policy | 9 | 2014 | 2677 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 1529 | 0.280 |
Why?
|
| Air Pollutants, Occupational | 1 | 2009 | 407 | 0.280 |
Why?
|
| Canada | 5 | 2022 | 2128 | 0.280 |
Why?
|
| Probability | 5 | 2021 | 2475 | 0.280 |
Why?
|
| Ambulatory Care | 5 | 2013 | 2781 | 0.280 |
Why?
|
| Hair | 7 | 2017 | 497 | 0.280 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 13630 | 0.270 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 125 | 0.270 |
Why?
|
| Severity of Illness Index | 16 | 2020 | 15840 | 0.270 |
Why?
|
| Myocardial Infarction | 8 | 2018 | 11891 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1406 | 0.270 |
Why?
|
| Causality | 4 | 2022 | 1242 | 0.260 |
Why?
|
| Incidence | 17 | 2021 | 21392 | 0.260 |
Why?
|
| Quality of Health Care | 2 | 2019 | 4360 | 0.260 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 4319 | 0.260 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 3448 | 0.260 |
Why?
|
| Hospitalization | 10 | 2022 | 10790 | 0.260 |
Why?
|
| Neurologic Examination | 3 | 2009 | 916 | 0.260 |
Why?
|
| Mothers | 2 | 2020 | 2186 | 0.260 |
Why?
|
| Anthracyclines | 1 | 2008 | 283 | 0.260 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2421 | 0.250 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6498 | 0.250 |
Why?
|
| Sample Size | 2 | 2020 | 840 | 0.250 |
Why?
|
| Human papillomavirus 16 | 1 | 2007 | 265 | 0.250 |
Why?
|
| Secondary Prevention | 2 | 2011 | 1548 | 0.240 |
Why?
|
| Hospitals, University | 3 | 2024 | 568 | 0.240 |
Why?
|
| Coronary Vessels | 10 | 2009 | 3112 | 0.240 |
Why?
|
| Assisted Living Facilities | 1 | 2024 | 26 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2005 | 1067 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 2418 | 0.240 |
Why?
|
| Australia | 3 | 2020 | 1289 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 3620 | 0.230 |
Why?
|
| Taxoids | 1 | 2008 | 669 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2011 | 539 | 0.230 |
Why?
|
| Brachytherapy | 7 | 2005 | 1238 | 0.230 |
Why?
|
| Indonesia | 4 | 2016 | 127 | 0.230 |
Why?
|
| Risk Factors | 28 | 2023 | 74359 | 0.230 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2024 | 47 | 0.230 |
Why?
|
| Benchmarking | 3 | 2018 | 1044 | 0.230 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 1919 | 0.230 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2003 | 74 | 0.230 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 25942 | 0.220 |
Why?
|
| Mercury Poisoning, Nervous System | 2 | 2017 | 8 | 0.220 |
Why?
|
| Body Burden | 4 | 2017 | 158 | 0.220 |
Why?
|
| Common Dolphins | 1 | 2023 | 1 | 0.220 |
Why?
|
| Bottle-Nosed Dolphin | 1 | 2023 | 2 | 0.220 |
Why?
|
| Crohn Disease | 2 | 2013 | 2275 | 0.220 |
Why?
|
| Aesculus | 1 | 2002 | 2 | 0.220 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 2138 | 0.210 |
Why?
|
| Methadone | 2 | 2023 | 320 | 0.210 |
Why?
|
| Disabled Persons | 1 | 2013 | 1223 | 0.210 |
Why?
|
| C-Reactive Protein | 3 | 2010 | 3839 | 0.210 |
Why?
|
| Delphi Technique | 3 | 2022 | 829 | 0.210 |
Why?
|
| Liver Cirrhosis | 3 | 2012 | 1931 | 0.210 |
Why?
|
| Oceans and Seas | 2 | 2020 | 47 | 0.210 |
Why?
|
| Algorithms | 6 | 2022 | 13981 | 0.210 |
Why?
|
| Adenoma | 2 | 2023 | 2148 | 0.210 |
Why?
|
| Mycoplasma Infections | 1 | 2023 | 120 | 0.210 |
Why?
|
| Hospitals, Public | 1 | 2024 | 201 | 0.210 |
Why?
|
| Disease Progression | 14 | 2017 | 13502 | 0.210 |
Why?
|
| Drug and Narcotic Control | 1 | 2023 | 145 | 0.210 |
Why?
|
| Indoles | 1 | 2011 | 1829 | 0.210 |
Why?
|
| Costs and Cost Analysis | 8 | 2022 | 1677 | 0.210 |
Why?
|
| Anemia | 2 | 2022 | 1511 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 7818 | 0.210 |
Why?
|
| Body Composition | 1 | 2012 | 2419 | 0.210 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2023 | 137 | 0.210 |
Why?
|
| Seeds | 1 | 2002 | 120 | 0.200 |
Why?
|
| Brazil | 3 | 2024 | 1218 | 0.200 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 4925 | 0.200 |
Why?
|
| Plant Preparations | 1 | 2002 | 94 | 0.200 |
Why?
|
| Prognosis | 15 | 2020 | 29658 | 0.200 |
Why?
|
| Medication Errors | 1 | 2008 | 784 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 9276 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2018 | 1164 | 0.200 |
Why?
|
| Food Contamination | 2 | 2016 | 192 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 1387 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4673 | 0.190 |
Why?
|
| Medical Informatics | 1 | 2009 | 732 | 0.190 |
Why?
|
| Environmental Exposure | 5 | 2020 | 4412 | 0.190 |
Why?
|
| Phoca | 1 | 2021 | 7 | 0.190 |
Why?
|
| Parasitic Diseases, Animal | 1 | 2001 | 5 | 0.190 |
Why?
|
| Venous Insufficiency | 1 | 2002 | 111 | 0.190 |
Why?
|
| Eagles | 1 | 2020 | 4 | 0.190 |
Why?
|
| Patient Preference | 2 | 2020 | 922 | 0.190 |
Why?
|
| Databases, Factual | 7 | 2020 | 8035 | 0.190 |
Why?
|
| Latvia | 1 | 2020 | 14 | 0.180 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 841 | 0.180 |
Why?
|
| Angina, Unstable | 3 | 2011 | 926 | 0.180 |
Why?
|
| Milk, Human | 2 | 2020 | 483 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1440 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 2049 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 3529 | 0.180 |
Why?
|
| Heart Transplantation | 9 | 2008 | 3224 | 0.180 |
Why?
|
| Human Activities | 1 | 2020 | 26 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 2 | 2022 | 901 | 0.180 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 393 | 0.180 |
Why?
|
| Asia | 2 | 2020 | 620 | 0.180 |
Why?
|
| Poland | 1 | 2020 | 196 | 0.170 |
Why?
|
| Manipulation, Spinal | 1 | 2000 | 21 | 0.170 |
Why?
|
| Evaluation Studies as Topic | 3 | 2012 | 1628 | 0.170 |
Why?
|
| Public Health | 3 | 2023 | 2653 | 0.170 |
Why?
|
| Exercise Test | 1 | 2008 | 2128 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 9185 | 0.170 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 8552 | 0.170 |
Why?
|
| Patient Access to Records | 1 | 2021 | 119 | 0.170 |
Why?
|
| Motorcycles | 1 | 2020 | 42 | 0.170 |
Why?
|
| Recombinant Proteins | 6 | 2009 | 6538 | 0.170 |
Why?
|
| Judgment | 1 | 2022 | 273 | 0.170 |
Why?
|
| Guanine | 2 | 2011 | 278 | 0.170 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 5889 | 0.170 |
Why?
|
| Glutamates | 2 | 2011 | 391 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 105 | 0.170 |
Why?
|
| Bandages | 1 | 2021 | 270 | 0.170 |
Why?
|
| Industry | 1 | 2001 | 361 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2023 | 496 | 0.170 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 934 | 0.170 |
Why?
|
| Policy | 3 | 2021 | 511 | 0.170 |
Why?
|
| Cohort Studies | 16 | 2024 | 41335 | 0.170 |
Why?
|
| Health Priorities | 1 | 2002 | 374 | 0.160 |
Why?
|
| Consensus | 3 | 2020 | 3113 | 0.160 |
Why?
|
| Predictive Value of Tests | 13 | 2020 | 15289 | 0.160 |
Why?
|
| Prevalence | 12 | 2023 | 15687 | 0.160 |
Why?
|
| Pharmacogenetics | 3 | 2012 | 680 | 0.160 |
Why?
|
| Health Status | 5 | 2023 | 4081 | 0.160 |
Why?
|
| Regression Analysis | 9 | 2021 | 6360 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7475 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2012 | 385 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2021 | 268 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2022 | 368 | 0.160 |
Why?
|
| Public Policy | 1 | 2023 | 560 | 0.160 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 859 | 0.160 |
Why?
|
| Health Services | 2 | 2022 | 753 | 0.160 |
Why?
|
| Systems Analysis | 1 | 2019 | 169 | 0.160 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 12531 | 0.150 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 39261 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 3527 | 0.150 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 293 | 0.150 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2004 | 2197 | 0.150 |
Why?
|
| North America | 2 | 2020 | 1284 | 0.150 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 549 | 0.150 |
Why?
|
| Denmark | 1 | 2020 | 760 | 0.150 |
Why?
|
| Young Adult | 13 | 2021 | 58741 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1035 | 0.150 |
Why?
|
| Time Factors | 21 | 2024 | 40165 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 631 | 0.150 |
Why?
|
| Africa | 1 | 2020 | 705 | 0.150 |
Why?
|
| Proline | 1 | 2019 | 457 | 0.140 |
Why?
|
| Tanzania | 3 | 2011 | 1383 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 8056 | 0.140 |
Why?
|
| Efficiency | 1 | 2020 | 477 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2023 | 883 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2021 | 810 | 0.140 |
Why?
|
| Chronic Disease | 7 | 2024 | 9287 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2022 | 3531 | 0.140 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 6828 | 0.140 |
Why?
|
| Heart Diseases | 4 | 2024 | 2809 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 529 | 0.140 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 11152 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 698 | 0.140 |
Why?
|
| HIV | 1 | 2004 | 1579 | 0.140 |
Why?
|
| Prospective Studies | 33 | 2022 | 54303 | 0.140 |
Why?
|
| Deep Brain Stimulation | 2 | 2016 | 820 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2020 | 773 | 0.130 |
Why?
|
| Multivariate Analysis | 9 | 2020 | 12159 | 0.130 |
Why?
|
| Dengue | 1 | 2019 | 254 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 272 | 0.130 |
Why?
|
| Biomedical Research | 4 | 2018 | 3426 | 0.130 |
Why?
|
| Oligopeptides | 2 | 2019 | 1187 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 13262 | 0.130 |
Why?
|
| Government Regulation | 1 | 2020 | 525 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2004 | 1894 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2020 | 619 | 0.130 |
Why?
|
| Retrospective Studies | 12 | 2024 | 80372 | 0.130 |
Why?
|
| Adolescent | 18 | 2023 | 87810 | 0.130 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 1399 | 0.130 |
Why?
|
| Efficiency, Organizational | 2 | 2010 | 697 | 0.130 |
Why?
|
| Survival Rate | 7 | 2016 | 12808 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2020 | 738 | 0.130 |
Why?
|
| Vitamins | 2 | 2022 | 1634 | 0.130 |
Why?
|
| Likelihood Functions | 2 | 2013 | 987 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2020 | 550 | 0.130 |
Why?
|
| Switzerland | 2 | 2013 | 323 | 0.130 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 2417 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 1055 | 0.130 |
Why?
|
| Cost Savings | 1 | 2021 | 920 | 0.130 |
Why?
|
| Comorbidity | 5 | 2023 | 10551 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 801 | 0.130 |
Why?
|
| Philosophy, Medical | 1 | 2015 | 79 | 0.120 |
Why?
|
| Mountaineering | 1 | 2015 | 45 | 0.120 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 130 | 0.120 |
Why?
|
| Age Factors | 7 | 2017 | 18416 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2020 | 2299 | 0.120 |
Why?
|
| Insurance, Health | 4 | 2020 | 2501 | 0.120 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2005 | 334 | 0.120 |
Why?
|
| Mastectomy | 1 | 2023 | 1832 | 0.120 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 136 | 0.120 |
Why?
|
| Cisplatin | 2 | 2011 | 1644 | 0.120 |
Why?
|
| Spinal Diseases | 1 | 2000 | 559 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 640 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2001 | 720 | 0.120 |
Why?
|
| Troponin | 1 | 2018 | 516 | 0.120 |
Why?
|
| Minke Whale | 1 | 2014 | 1 | 0.120 |
Why?
|
| Quinolines | 1 | 2020 | 759 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 766 | 0.120 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20080 | 0.120 |
Why?
|
| Drug-Eluting Stents | 3 | 2010 | 757 | 0.120 |
Why?
|
| Morbidity | 3 | 2021 | 1765 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2020 | 1139 | 0.120 |
Why?
|
| Altitude Sickness | 1 | 2015 | 91 | 0.120 |
Why?
|
| Acute Disease | 4 | 2021 | 7269 | 0.120 |
Why?
|
| Cattle | 2 | 2018 | 3847 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 1431 | 0.120 |
Why?
|
| Altitude | 1 | 2015 | 159 | 0.120 |
Why?
|
| Infant, Newborn | 7 | 2022 | 26181 | 0.120 |
Why?
|
| Accidental Falls | 1 | 2022 | 1056 | 0.110 |
Why?
|
| Movement | 1 | 2021 | 1474 | 0.110 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 136 | 0.110 |
Why?
|
| Pericardium | 1 | 2018 | 675 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6315 | 0.110 |
Why?
|
| Telephone | 1 | 2017 | 624 | 0.110 |
Why?
|
| Reoperation | 3 | 2018 | 4291 | 0.110 |
Why?
|
| Politics | 1 | 2020 | 814 | 0.110 |
Why?
|
| Echocardiography, Stress | 2 | 2005 | 134 | 0.110 |
Why?
|
| Patient Participation | 2 | 2021 | 1439 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2013 | 52 | 0.110 |
Why?
|
| Hand Strength | 1 | 2016 | 452 | 0.110 |
Why?
|
| Tremor | 2 | 2017 | 187 | 0.110 |
Why?
|
| Subthalamic Nucleus | 1 | 2016 | 193 | 0.110 |
Why?
|
| Cervical Vertebrae | 1 | 2000 | 978 | 0.110 |
Why?
|
| Sleep | 1 | 2009 | 4751 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2001 | 1486 | 0.110 |
Why?
|
| Genetic Counseling | 1 | 2017 | 624 | 0.110 |
Why?
|
| Cetacea | 1 | 2012 | 5 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 7806 | 0.110 |
Why?
|
| Narcolepsy | 2 | 2007 | 199 | 0.110 |
Why?
|
| Exercise | 3 | 2020 | 5787 | 0.110 |
Why?
|
| Physical Examination | 1 | 2019 | 1244 | 0.110 |
Why?
|
| Tunica Intima | 3 | 2008 | 459 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2017 | 510 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2061 | 0.110 |
Why?
|
| Hospice Care | 1 | 2020 | 692 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2021 | 1866 | 0.110 |
Why?
|
| Infant | 5 | 2020 | 36060 | 0.110 |
Why?
|
| Administrative Personnel | 1 | 2014 | 182 | 0.100 |
Why?
|
| Body Weight | 1 | 2003 | 4611 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3707 | 0.100 |
Why?
|
| Buprenorphine | 1 | 2020 | 654 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1403 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2016 | 5649 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2004 | 560 | 0.100 |
Why?
|
| Monte Carlo Method | 2 | 2008 | 1257 | 0.100 |
Why?
|
| Inpatients | 1 | 2024 | 2581 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 3388 | 0.100 |
Why?
|
| Forecasting | 2 | 2017 | 2932 | 0.100 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 3763 | 0.100 |
Why?
|
| Models, Econometric | 2 | 2010 | 216 | 0.100 |
Why?
|
| Poisson Distribution | 2 | 2011 | 507 | 0.100 |
Why?
|
| Guaiac | 2 | 2023 | 13 | 0.100 |
Why?
|
| Inflammation | 1 | 2012 | 10756 | 0.100 |
Why?
|
| Epigenomics | 1 | 2018 | 936 | 0.100 |
Why?
|
| European Union | 2 | 2014 | 157 | 0.100 |
Why?
|
| World Health Organization | 3 | 2020 | 1312 | 0.100 |
Why?
|
| Protein Precursors | 2 | 2006 | 1134 | 0.100 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2011 | 82 | 0.100 |
Why?
|
| Foot Injuries | 1 | 2013 | 149 | 0.100 |
Why?
|
| Legislation, Drug | 1 | 2014 | 214 | 0.100 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 7021 | 0.100 |
Why?
|
| Intestinal Volvulus | 1 | 2012 | 81 | 0.100 |
Why?
|
| Cardiology | 1 | 2023 | 1723 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2006 | 530 | 0.100 |
Why?
|
| British Columbia | 2 | 2023 | 240 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2016 | 2295 | 0.100 |
Why?
|
| Conservation of Natural Resources | 1 | 2014 | 211 | 0.100 |
Why?
|
| Immunization | 1 | 2016 | 1227 | 0.100 |
Why?
|
| Disclosure | 1 | 2017 | 738 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2006 | 515 | 0.090 |
Why?
|
| Wound Infection | 1 | 2013 | 244 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2015 | 452 | 0.090 |
Why?
|
| Health Services for the Aged | 1 | 2013 | 259 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2022 | 3392 | 0.090 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 368 | 0.090 |
Why?
|
| Anti-HIV Agents | 2 | 2004 | 4491 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2019 | 878 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1152 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2022 | 1528 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2024 | 3476 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 4407 | 0.090 |
Why?
|
| Age Distribution | 3 | 2016 | 2893 | 0.090 |
Why?
|
| Immunosuppressive Agents | 5 | 2004 | 4166 | 0.090 |
Why?
|
| Ecosystem | 3 | 2021 | 485 | 0.090 |
Why?
|
| Urinary Incontinence | 1 | 2015 | 495 | 0.090 |
Why?
|
| Child | 9 | 2020 | 79806 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 730 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1791 | 0.090 |
Why?
|
| Plasma Cells | 1 | 2013 | 591 | 0.090 |
Why?
|
| Wound Healing | 1 | 2021 | 2788 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8624 | 0.090 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2010 | 52 | 0.090 |
Why?
|
| Volatilization | 1 | 2009 | 79 | 0.090 |
Why?
|
| Coumarins | 1 | 2010 | 119 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1677 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2013 | 410 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2004 | 777 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2017 | 2659 | 0.080 |
Why?
|
| Geologic Sediments | 1 | 2009 | 79 | 0.080 |
Why?
|
| Breast Feeding | 2 | 2008 | 1355 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2008 | 2932 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2210 | 0.080 |
Why?
|
| Anesthesiology | 1 | 1999 | 1116 | 0.080 |
Why?
|
| Pneumonia | 1 | 2001 | 2131 | 0.080 |
Why?
|
| Multiple System Atrophy | 1 | 2010 | 129 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2007 | 1826 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2649 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 3 | 2007 | 2884 | 0.080 |
Why?
|
| Adenosine | 2 | 2004 | 834 | 0.080 |
Why?
|
| Medicaid | 1 | 2002 | 2815 | 0.080 |
Why?
|
| Primary Health Care | 3 | 2011 | 4647 | 0.080 |
Why?
|
| Health Resources | 2 | 2013 | 935 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2021 | 3185 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 755 | 0.080 |
Why?
|
| Czech Republic | 1 | 2008 | 73 | 0.080 |
Why?
|
| Biopsy | 2 | 2017 | 6771 | 0.080 |
Why?
|
| Long-Term Care | 2 | 2011 | 632 | 0.080 |
Why?
|
| Carboplatin | 1 | 2011 | 788 | 0.080 |
Why?
|
| Animals | 13 | 2023 | 167963 | 0.080 |
Why?
|
| Beta Particles | 2 | 2005 | 47 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2018 | 1870 | 0.080 |
Why?
|
| Sex Factors | 5 | 2020 | 10547 | 0.080 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3736 | 0.080 |
Why?
|
| Terminal Care | 1 | 2020 | 1758 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 844 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2022 | 4373 | 0.080 |
Why?
|
| United States | 9 | 2021 | 72461 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 2526 | 0.070 |
Why?
|
| Sirolimus | 2 | 2005 | 1547 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12965 | 0.070 |
Why?
|
| Levodopa | 2 | 2010 | 217 | 0.070 |
Why?
|
| Antibodies, Bacterial | 1 | 2013 | 1468 | 0.070 |
Why?
|
| Climate Change | 1 | 2014 | 488 | 0.070 |
Why?
|
| Anticoagulants | 3 | 2014 | 4897 | 0.070 |
Why?
|
| Community Networks | 1 | 2009 | 201 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2022 | 12427 | 0.070 |
Why?
|
| Opiate Substitution Treatment | 2 | 2023 | 436 | 0.070 |
Why?
|
| Penicillamine | 1 | 2007 | 60 | 0.070 |
Why?
|
| Multiple Myeloma | 2 | 2016 | 5130 | 0.070 |
Why?
|
| HIV Infections | 3 | 2023 | 17165 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2022 | 1117 | 0.070 |
Why?
|
| Vaccines | 1 | 2016 | 832 | 0.070 |
Why?
|
| Medical Record Linkage | 1 | 2009 | 288 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2002 | 733 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2009 | 150 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2010 | 317 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2008 | 319 | 0.070 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 409 | 0.070 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2007 | 46 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2013 | 1354 | 0.070 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2007 | 72 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2554 | 0.070 |
Why?
|
| ROC Curve | 3 | 2009 | 3568 | 0.070 |
Why?
|
| Seafood | 1 | 2009 | 390 | 0.070 |
Why?
|
| Epilepsy | 1 | 2022 | 3267 | 0.070 |
Why?
|
| Parkinsonian Disorders | 2 | 2010 | 284 | 0.070 |
Why?
|
| Fishes | 1 | 2009 | 601 | 0.070 |
Why?
|
| Postoperative Complications | 5 | 2023 | 15697 | 0.070 |
Why?
|
| Drug Costs | 3 | 2019 | 1185 | 0.070 |
Why?
|
| Patient Care | 1 | 2012 | 624 | 0.070 |
Why?
|
| Family | 1 | 2017 | 3189 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2007 | 318 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 859 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 2693 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 2 | 2009 | 2365 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 442 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2017 | 2529 | 0.070 |
Why?
|
| Leg | 3 | 2006 | 1090 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2015 | 1956 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2010 | 873 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 395 | 0.060 |
Why?
|
| Interferons | 1 | 2009 | 705 | 0.060 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3085 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2007 | 384 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1599 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3610 | 0.060 |
Why?
|
| Length of Stay | 6 | 2012 | 6479 | 0.060 |
Why?
|
| Angina Pectoris | 1 | 2009 | 969 | 0.060 |
Why?
|
| North Sea | 2 | 2003 | 4 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2010 | 763 | 0.060 |
Why?
|
| Observer Variation | 5 | 2006 | 2601 | 0.060 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 349 | 0.060 |
Why?
|
| Cause of Death | 3 | 2016 | 3725 | 0.060 |
Why?
|
| Hemophilia B | 1 | 2005 | 84 | 0.060 |
Why?
|
| Developing Countries | 3 | 2014 | 2868 | 0.060 |
Why?
|
| Arctic Regions | 2 | 2020 | 25 | 0.060 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2004 | 39 | 0.060 |
Why?
|
| Research Report | 2 | 2022 | 370 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 1343 | 0.060 |
Why?
|
| Hearing Disorders | 1 | 2005 | 126 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2009 | 1636 | 0.060 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2005 | 99 | 0.060 |
Why?
|
| Jordan | 1 | 2024 | 73 | 0.060 |
Why?
|
| Genotype | 3 | 2012 | 12960 | 0.060 |
Why?
|
| Travel | 2 | 2020 | 785 | 0.060 |
Why?
|
| Self-Examination | 1 | 2004 | 71 | 0.060 |
Why?
|
| Drug Therapy | 2 | 2020 | 504 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3465 | 0.060 |
Why?
|
| Actuarial Analysis | 1 | 2004 | 374 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 3602 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 749 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2011 | 1736 | 0.060 |
Why?
|
| Parapoxvirus | 1 | 2003 | 2 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2004 | 200 | 0.060 |
Why?
|
| Poxviridae Infections | 1 | 2003 | 12 | 0.060 |
Why?
|
| Ergolines | 1 | 2003 | 57 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4775 | 0.060 |
Why?
|
| Oxygen | 1 | 2015 | 4193 | 0.060 |
Why?
|
| Self Report | 1 | 2015 | 3711 | 0.050 |
Why?
|
| Metallurgy | 2 | 2017 | 95 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2014 | 2511 | 0.050 |
Why?
|
| Finland | 1 | 2024 | 603 | 0.050 |
Why?
|
| Calcitriol | 2 | 2002 | 297 | 0.050 |
Why?
|
| Mycoplasma genitalium | 1 | 2023 | 12 | 0.050 |
Why?
|
| Software | 2 | 2015 | 4419 | 0.050 |
Why?
|
| Hospital Units | 1 | 2004 | 142 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2003 | 79 | 0.050 |
Why?
|
| Dolphins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12293 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 2006 | 978 | 0.050 |
Why?
|
| Whales | 1 | 2002 | 30 | 0.050 |
Why?
|
| Prospective Payment System | 1 | 2003 | 136 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 3484 | 0.050 |
Why?
|
| Veins | 1 | 2007 | 765 | 0.050 |
Why?
|
| Polysomnography | 1 | 2009 | 1825 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2022 | 5425 | 0.050 |
Why?
|
| Social Work | 1 | 2024 | 158 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 383 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2017 | 12766 | 0.050 |
Why?
|
| Oregon | 1 | 2002 | 148 | 0.050 |
Why?
|
| Linear Models | 2 | 2021 | 5877 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 343 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 392 | 0.050 |
Why?
|
| Healthy Worker Effect | 1 | 2001 | 29 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4642 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1297 | 0.050 |
Why?
|
| Hemophilia A | 1 | 2005 | 359 | 0.050 |
Why?
|
| Chest Pain | 2 | 2006 | 1106 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2013 | 9716 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1939 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 206 | 0.050 |
Why?
|
| Femur Neck | 1 | 2003 | 312 | 0.050 |
Why?
|
| Hemiplegia | 1 | 2022 | 136 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2008 | 1108 | 0.050 |
Why?
|
| Paraplegia | 1 | 2022 | 162 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 8555 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8515 | 0.050 |
Why?
|
| Hemodynamics | 3 | 2008 | 4174 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 415 | 0.050 |
Why?
|
| Calcinosis | 2 | 2009 | 1476 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2009 | 1207 | 0.050 |
Why?
|
| Bone Density | 3 | 2003 | 3534 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9467 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2024 | 3323 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2012 | 2869 | 0.050 |
Why?
|
| Zambia | 1 | 2021 | 257 | 0.050 |
Why?
|
| Deafness | 1 | 2005 | 457 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 465 | 0.050 |
Why?
|
| Echocardiography | 2 | 2006 | 4981 | 0.050 |
Why?
|
| Strontium Radioisotopes | 3 | 2005 | 18 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 752 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2005 | 595 | 0.040 |
Why?
|
| Models, Animal | 1 | 2007 | 2117 | 0.040 |
Why?
|
| Torque | 1 | 2020 | 132 | 0.040 |
Why?
|
| Retirement | 1 | 2001 | 199 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2001 | 450 | 0.040 |
Why?
|
| Hostility | 1 | 2000 | 183 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2024 | 5523 | 0.040 |
Why?
|
| Cost Control | 1 | 2002 | 630 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2007 | 1089 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2009 | 2325 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2007 | 1927 | 0.040 |
Why?
|
| Lipids | 1 | 2011 | 3336 | 0.040 |
Why?
|
| Atherosclerosis | 2 | 2006 | 3517 | 0.040 |
Why?
|
| Sprains and Strains | 1 | 2000 | 75 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1306 | 0.040 |
Why?
|
| Patient Rights | 1 | 2020 | 125 | 0.040 |
Why?
|
| Neck Muscles | 1 | 2000 | 100 | 0.040 |
Why?
|
| Ischemia | 2 | 2005 | 1893 | 0.040 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.040 |
Why?
|
| Vaccination | 2 | 2022 | 3361 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2002 | 349 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2020 | 127 | 0.040 |
Why?
|
| Career Mobility | 1 | 2001 | 258 | 0.040 |
Why?
|
| Troponin T | 1 | 2004 | 774 | 0.040 |
Why?
|
| Critical Illness | 2 | 2010 | 2709 | 0.040 |
Why?
|
| Triage | 1 | 2006 | 987 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6238 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2011 | 2313 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 3 | 2005 | 107 | 0.040 |
Why?
|
| Coronary Artery Bypass | 3 | 2007 | 2272 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2007 | 20509 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2019 | 461 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 494 | 0.040 |
Why?
|
| Logistic Models | 4 | 2024 | 13314 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 1377 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2021 | 280 | 0.040 |
Why?
|
| Patient Selection | 2 | 2008 | 4283 | 0.040 |
Why?
|
| Premature Birth | 1 | 2011 | 1771 | 0.040 |
Why?
|
| International Cooperation | 2 | 2016 | 1433 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 29932 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2003 | 835 | 0.040 |
Why?
|
| Health Personnel | 1 | 2012 | 3310 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2020 | 691 | 0.040 |
Why?
|
| Water Pollutants, Chemical | 1 | 2002 | 354 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1064 | 0.040 |
Why?
|
| Advance Directives | 1 | 2020 | 248 | 0.040 |
Why?
|
| Anger | 1 | 2000 | 401 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1581 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2024 | 6381 | 0.040 |
Why?
|
| Hyperemia | 3 | 2004 | 221 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2023 | 1347 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 1745 | 0.040 |
Why?
|
| Aging | 1 | 2016 | 8651 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2004 | 976 | 0.040 |
Why?
|
| South Africa | 1 | 2023 | 1821 | 0.040 |
Why?
|
| Morals | 1 | 2020 | 289 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2020 | 2435 | 0.040 |
Why?
|
| Femur | 1 | 2003 | 1302 | 0.040 |
Why?
|
| Autopsy | 1 | 2001 | 1007 | 0.040 |
Why?
|
| Ticlopidine | 1 | 2022 | 895 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2020 | 559 | 0.030 |
Why?
|
| Calibration | 1 | 2019 | 816 | 0.030 |
Why?
|
| Public Health Practice | 1 | 2019 | 218 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2010 | 2844 | 0.030 |
Why?
|
| Pregnancy | 3 | 2011 | 29749 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 26951 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2004 | 1194 | 0.030 |
Why?
|
| Retreatment | 2 | 2009 | 600 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 3340 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2005 | 2128 | 0.030 |
Why?
|
| Vasodilation | 3 | 2006 | 962 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2013 | 3598 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2020 | 732 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2016 | 42063 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 10181 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2022 | 821 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 2276 | 0.030 |
Why?
|
| Pyrroles | 1 | 2002 | 1137 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2006 | 2283 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 8547 | 0.030 |
Why?
|
| Drug Implants | 2 | 2007 | 230 | 0.030 |
Why?
|
| Hypertension | 3 | 2021 | 8594 | 0.030 |
Why?
|
| Health Promotion | 1 | 2008 | 2206 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 2634 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2004 | 2118 | 0.030 |
Why?
|
| Mediastinum | 1 | 2017 | 266 | 0.030 |
Why?
|
| Blood Pressure | 4 | 2005 | 8525 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17790 | 0.030 |
Why?
|
| Comprehension | 1 | 2021 | 618 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 14495 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2022 | 1124 | 0.030 |
Why?
|
| Recurrence | 4 | 2016 | 8482 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2022 | 919 | 0.030 |
Why?
|
| Japan | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Epidemics | 1 | 2021 | 510 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 4902 | 0.030 |
Why?
|
| Attitude | 1 | 2020 | 777 | 0.030 |
Why?
|
| Ataxia | 1 | 2017 | 305 | 0.030 |
Why?
|
| Antarctic Regions | 1 | 2014 | 13 | 0.030 |
Why?
|
| Immunity | 1 | 2020 | 998 | 0.030 |
Why?
|
| Ice Cover | 1 | 2014 | 8 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2005 | 2881 | 0.030 |
Why?
|
| Egypt | 1 | 2014 | 98 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2016 | 250 | 0.030 |
Why?
|
| Population Density | 1 | 2014 | 192 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2007 | 2758 | 0.030 |
Why?
|
| Health Surveys | 1 | 2003 | 4063 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2017 | 3486 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2326 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 395 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 5496 | 0.030 |
Why?
|
| Endosonography | 1 | 2017 | 607 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2852 | 0.030 |
Why?
|
| Pediatrics | 1 | 2008 | 3586 | 0.030 |
Why?
|
| Planning Techniques | 1 | 2012 | 82 | 0.030 |
Why?
|
| Calcium | 1 | 2006 | 5725 | 0.030 |
Why?
|
| Contrast Media | 4 | 2007 | 5305 | 0.030 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2012 | 14 | 0.030 |
Why?
|
| Pensions | 1 | 2012 | 15 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 2012 | 189 | 0.030 |
Why?
|
| Demography | 2 | 2007 | 1650 | 0.030 |
Why?
|
| Anorexia | 1 | 2012 | 154 | 0.020 |
Why?
|
| Mesentery | 1 | 2012 | 202 | 0.020 |
Why?
|
| Forearm Injuries | 1 | 2012 | 68 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 2471 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2014 | 306 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1999 | 1155 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 4433 | 0.020 |
Why?
|
| Home Nursing | 1 | 2012 | 92 | 0.020 |
Why?
|
| Schools | 1 | 2020 | 1480 | 0.020 |
Why?
|
| Tissue Donors | 2 | 1999 | 2313 | 0.020 |
Why?
|
| Malaria | 1 | 2021 | 1226 | 0.020 |
Why?
|
| Fear | 1 | 2020 | 1462 | 0.020 |
Why?
|
| Vascular Patency | 2 | 2004 | 901 | 0.020 |
Why?
|
| Enteritis | 1 | 2012 | 162 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2002 | 2560 | 0.020 |
Why?
|
| Shy-Drager Syndrome | 1 | 2010 | 9 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2021 | 2985 | 0.020 |
Why?
|
| Cognition Disorders | 2 | 2020 | 3976 | 0.020 |
Why?
|
| Glaucoma | 1 | 2021 | 1182 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2012 | 376 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36290 | 0.020 |
Why?
|
| Health Planning | 1 | 2012 | 232 | 0.020 |
Why?
|
| Mongolia | 1 | 2010 | 93 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 3880 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2116 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3150 | 0.020 |
Why?
|
| Plant Lectins | 1 | 1991 | 103 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2016 | 665 | 0.020 |
Why?
|
| Social Support | 1 | 2000 | 2145 | 0.020 |
Why?
|
| Rib Fractures | 1 | 2012 | 128 | 0.020 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5397 | 0.020 |
Why?
|
| Thalidomide | 1 | 2016 | 884 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2021 | 2688 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3301 | 0.020 |
Why?
|
| Syndrome | 2 | 2007 | 3280 | 0.020 |
Why?
|
| Disaccharides | 1 | 1991 | 170 | 0.020 |
Why?
|
| Aspirin | 1 | 2022 | 3364 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2004 | 2611 | 0.020 |
Why?
|
| Osteoporosis | 1 | 1999 | 1600 | 0.020 |
Why?
|
| Substance P | 1 | 1991 | 333 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6544 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2012 | 363 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1722 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 3201 | 0.020 |
Why?
|
| Access to Information | 1 | 2012 | 320 | 0.020 |
Why?
|
| Cerebellar Ataxia | 1 | 2010 | 149 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2012 | 965 | 0.020 |
Why?
|
| Seizures | 1 | 2022 | 2917 | 0.020 |
Why?
|
| Microcirculation | 2 | 2004 | 1278 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1793 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7343 | 0.020 |
Why?
|
| Humeral Fractures | 1 | 2012 | 282 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3763 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2362 | 0.020 |
Why?
|
| Risk | 2 | 2017 | 9631 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2020 | 2041 | 0.020 |
Why?
|
| Vitamin D | 1 | 2022 | 3291 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2010 | 429 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 312 | 0.020 |
Why?
|
| Hypotension, Orthostatic | 1 | 2010 | 256 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2007 | 56 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11071 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 1809 | 0.020 |
Why?
|
| Aminophylline | 1 | 2006 | 41 | 0.020 |
Why?
|
| DNA, Viral | 2 | 2004 | 2194 | 0.020 |
Why?
|
| Telemedicine | 1 | 2024 | 3018 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3836 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2006 | 143 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 4925 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 989 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 3986 | 0.020 |
Why?
|
| Hemorrhage | 2 | 2010 | 3600 | 0.020 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 166 | 0.020 |
Why?
|
| Technology, High-Cost | 1 | 2005 | 32 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 10827 | 0.020 |
Why?
|
| Home Care Services | 1 | 2012 | 654 | 0.020 |
Why?
|
| Warfarin | 1 | 2014 | 1518 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2012 | 702 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2002 | 2897 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 1612 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 1166 | 0.020 |
Why?
|
| Myocardial Ischemia | 2 | 2006 | 2164 | 0.020 |
Why?
|
| Genome, Human | 1 | 2018 | 4417 | 0.020 |
Why?
|
| Hindlimb | 1 | 2007 | 510 | 0.020 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2006 | 152 | 0.020 |
Why?
|
| Pokeweed Mitogens | 1 | 2004 | 38 | 0.010 |
Why?
|
| Prisons | 1 | 2006 | 170 | 0.010 |
Why?
|
| Copper | 1 | 2007 | 368 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2004 | 168 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7408 | 0.010 |
Why?
|
| Concanavalin A | 1 | 2004 | 190 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2004 | 158 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2005 | 5201 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 2004 | 185 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1991 | 1889 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2005 | 573 | 0.010 |
Why?
|
| Sleep, REM | 1 | 2007 | 593 | 0.010 |
Why?
|
| Family Practice | 1 | 2006 | 510 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2021 | 12914 | 0.010 |
Why?
|
| Hip Fractures | 1 | 2012 | 989 | 0.010 |
Why?
|
| Age of Onset | 1 | 2010 | 3301 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2003 | 182 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1907 | 0.010 |
Why?
|
| Factor VIII | 1 | 2005 | 349 | 0.010 |
Why?
|
| Movement Disorders | 1 | 2007 | 459 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 546 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 823 | 0.010 |
Why?
|
| Pacific Ocean | 1 | 2002 | 15 | 0.010 |
Why?
|
| Halogens | 1 | 2002 | 13 | 0.010 |
Why?
|
| Water Movements | 1 | 2002 | 17 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1535 | 0.010 |
Why?
|
| Time | 1 | 2004 | 545 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2005 | 956 | 0.010 |
Why?
|
| Albumins | 1 | 2005 | 575 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2042 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2004 | 577 | 0.010 |
Why?
|
| Perfusion | 1 | 2007 | 1376 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 1155 | 0.010 |
Why?
|
| Asthma | 1 | 2021 | 6172 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 670 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 2005 | 597 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 2176 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 1991 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 2420 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 2221 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2005 | 701 | 0.010 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2000 | 56 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2003 | 657 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 1516 | 0.010 |
Why?
|
| Caregivers | 1 | 2012 | 2224 | 0.010 |
Why?
|
| Fluorocarbons | 1 | 2005 | 488 | 0.010 |
Why?
|
| Communication | 1 | 2014 | 3849 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2234 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 2819 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 1529 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 1818 | 0.010 |
Why?
|
| Life Style | 1 | 2011 | 3896 | 0.010 |
Why?
|
| Dobutamine | 1 | 1999 | 116 | 0.010 |
Why?
|
| Emergencies | 1 | 2006 | 1211 | 0.010 |
Why?
|
| Interleukins | 1 | 2004 | 785 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4107 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2014 | 3790 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2002 | 720 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 1570 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1148 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1999 | 345 | 0.010 |
Why?
|
| Diet | 1 | 2016 | 8010 | 0.010 |
Why?
|
| Placebos | 1 | 2002 | 1668 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2007 | 2062 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 2569 | 0.010 |
Why?
|
| Internal Medicine | 1 | 2004 | 1048 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4573 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 1999 | 531 | 0.010 |
Why?
|
| Ultrasonography | 2 | 2000 | 5961 | 0.010 |
Why?
|
| Obesity | 1 | 1999 | 12922 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 1959 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 17624 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 2571 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 1958 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1999 | 854 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 3322 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 5209 | 0.010 |
Why?
|
| Hospitals | 1 | 2007 | 3928 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12446 | 0.010 |
Why?
|
| Estrogens | 1 | 1999 | 1520 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4357 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2004 | 2660 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 6414 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 3520 | 0.010 |
Why?
|
| Triglycerides | 1 | 1999 | 2476 | 0.010 |
Why?
|
| Heart Rate | 1 | 2003 | 4179 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9280 | 0.010 |
Why?
|
| Ribosome Inactivating Proteins | 1 | 1991 | 7 | 0.010 |
Why?
|
| Agglutination | 1 | 1991 | 41 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 7509 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4810 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1991 | 410 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 2924 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2004 | 3127 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 22053 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1991 | 869 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4048 | 0.010 |
Why?
|
| Lectins | 1 | 1991 | 484 | 0.000 |
Why?
|
| Radiography | 1 | 1999 | 6965 | 0.000 |
Why?
|
| Testosterone | 1 | 1999 | 2470 | 0.000 |
Why?
|
| Glycosylation | 1 | 1991 | 1096 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1991 | 2208 | 0.000 |
Why?
|